Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy
Nabilone, a synthetic cannabinoid, and Prochlorperazine were compared in a double-blind crossover study of 34 patients with lung cancer undergoing a 3-day schedule of chemotherapy with Cyclophosphamide, Adriamycin and Etoposide. Symptom scores were significantly better for patients on nabilone for n...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 1983-11, Vol.48 (5), p.657-663 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 663 |
|---|---|
| container_issue | 5 |
| container_start_page | 657 |
| container_title | British journal of cancer |
| container_volume | 48 |
| creator | Ahmedzai, S Carlyle, D L Calder, I T Moran, F |
| description | Nabilone, a synthetic cannabinoid, and Prochlorperazine were compared in a double-blind crossover study of 34 patients with lung cancer undergoing a 3-day schedule of chemotherapy with Cyclophosphamide, Adriamycin and Etoposide. Symptom scores were significantly better for patients on nabilone for nausea, retching and vomiting (P less than 0.05). Fewer subjects vomited with nabilone (P = 0.05) and the number of vomiting episodes was lower (P less than 0.05); no patients on nabilone required additional parenteral anti-emetic. More patients preferred nabilone for anti-emetic control (P less than 0.005). Adverse effects common with nabilone were drowsiness (57%), postural dizziness (35%) and lightheadedness (18%). Euphoria was seen in 14% and a "high" in 7%. Erect systolic blood pressure was lower in nabilone patients on Day 1 (P = 0.05) but postural hypotension was a major problem in only 7%. Nabilone is an effective oral anti-emetic drug for moderately toxic chemotherapy, but the range and unpredictability of its side-effects warrant caution in its use. |
| doi_str_mv | 10.1038/bjc.1983.247 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2011510</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>13756769</sourcerecordid><originalsourceid>FETCH-LOGICAL-c502t-50691833a5b9bcc168e0a61fe7665e74cca6021461c3924ed22fbdab19cc94093</originalsourceid><addsrcrecordid>eNp1kU2P0zAYhC0EWkrhxhXJB8SpKf5InPiCtFqxgLQSFzhbzps3ravULnayIv8eZ1tVcOBk2fNoxpoh5C1nW85k87E9wJbrRm5FWT8jK15JUfBG1M_JijFWF0wL9pK8SumQr5o19Q25UZJXrGQrArd-dAUecXRAse8dWJip9R0dw28Hbpxp6Km3rRuCxw21NM1-3D_hYP0i-OC6DXWeDpPfLY-AkcIejyFz0Z7m1-RFb4eEby7nmvy8__zj7mvx8P3Lt7vbhwIqJsaiYkrzRkpbtboF4KpBZhXvsVaqwroEsIoJXioOUosSOyH6trMt1wC6ZFquyaez72lqj9gB-jHawZyiO9o4m2Cd-Vfxbm924dEIxnmVu1yTDxeDGH5NmEZzdAlwGKzHMCXDZV2pWi1JmzMIMaQUsb-GcGaWUUwexSyjmDxKxt_9_bErfFkh6-8vuk1ghz7mDl26YrrSvGYyY8UZS1nxO4zmEKboc6X_i6Vn3ttxinj1y9DCLMgfKjywCQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>13756769</pqid></control><display><type>article</type><title>Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy</title><source>MEDLINE</source><source>Nature Journals Online</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Ahmedzai, S ; Carlyle, D L ; Calder, I T ; Moran, F</creator><creatorcontrib>Ahmedzai, S ; Carlyle, D L ; Calder, I T ; Moran, F</creatorcontrib><description>Nabilone, a synthetic cannabinoid, and Prochlorperazine were compared in a double-blind crossover study of 34 patients with lung cancer undergoing a 3-day schedule of chemotherapy with Cyclophosphamide, Adriamycin and Etoposide. Symptom scores were significantly better for patients on nabilone for nausea, retching and vomiting (P less than 0.05). Fewer subjects vomited with nabilone (P = 0.05) and the number of vomiting episodes was lower (P less than 0.05); no patients on nabilone required additional parenteral anti-emetic. More patients preferred nabilone for anti-emetic control (P less than 0.005). Adverse effects common with nabilone were drowsiness (57%), postural dizziness (35%) and lightheadedness (18%). Euphoria was seen in 14% and a "high" in 7%. Erect systolic blood pressure was lower in nabilone patients on Day 1 (P = 0.05) but postural hypotension was a major problem in only 7%. Nabilone is an effective oral anti-emetic drug for moderately toxic chemotherapy, but the range and unpredictability of its side-effects warrant caution in its use.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.1983.247</identifier><identifier>PMID: 6315040</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adult ; Aged ; Antiemetics - adverse effects ; Antiemetics - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Carcinoma, Small Cell - drug therapy ; Clinical Trials as Topic ; Dizziness - chemically induced ; Double-Blind Method ; Dronabinol - adverse effects ; Dronabinol - analogs & derivatives ; Dronabinol - therapeutic use ; Drug Resistance ; Drug toxicity and drugs side effects treatment ; Epidemiology ; Female ; Humans ; Lung Neoplasms - drug therapy ; Male ; Medical sciences ; Middle Aged ; Molecular Medicine ; Nausea - prevention & control ; Oncology ; original-article ; Pharmacology. Drug treatments ; Prochlorperazine - therapeutic use ; Sleep Stages ; Toxicity: digestive system ; Vomiting - prevention & control</subject><ispartof>British journal of cancer, 1983-11, Vol.48 (5), p.657-663</ispartof><rights>Cancer Research Campaign 1983</rights><rights>1984 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c502t-50691833a5b9bcc168e0a61fe7665e74cca6021461c3924ed22fbdab19cc94093</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011510/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011510/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,2727,27924,27925,41488,42557,51319,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=9591703$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6315040$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ahmedzai, S</creatorcontrib><creatorcontrib>Carlyle, D L</creatorcontrib><creatorcontrib>Calder, I T</creatorcontrib><creatorcontrib>Moran, F</creatorcontrib><title>Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Nabilone, a synthetic cannabinoid, and Prochlorperazine were compared in a double-blind crossover study of 34 patients with lung cancer undergoing a 3-day schedule of chemotherapy with Cyclophosphamide, Adriamycin and Etoposide. Symptom scores were significantly better for patients on nabilone for nausea, retching and vomiting (P less than 0.05). Fewer subjects vomited with nabilone (P = 0.05) and the number of vomiting episodes was lower (P less than 0.05); no patients on nabilone required additional parenteral anti-emetic. More patients preferred nabilone for anti-emetic control (P less than 0.005). Adverse effects common with nabilone were drowsiness (57%), postural dizziness (35%) and lightheadedness (18%). Euphoria was seen in 14% and a "high" in 7%. Erect systolic blood pressure was lower in nabilone patients on Day 1 (P = 0.05) but postural hypotension was a major problem in only 7%. Nabilone is an effective oral anti-emetic drug for moderately toxic chemotherapy, but the range and unpredictability of its side-effects warrant caution in its use.</description><subject>Adult</subject><subject>Aged</subject><subject>Antiemetics - adverse effects</subject><subject>Antiemetics - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Carcinoma, Small Cell - drug therapy</subject><subject>Clinical Trials as Topic</subject><subject>Dizziness - chemically induced</subject><subject>Double-Blind Method</subject><subject>Dronabinol - adverse effects</subject><subject>Dronabinol - analogs & derivatives</subject><subject>Dronabinol - therapeutic use</subject><subject>Drug Resistance</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Nausea - prevention & control</subject><subject>Oncology</subject><subject>original-article</subject><subject>Pharmacology. Drug treatments</subject><subject>Prochlorperazine - therapeutic use</subject><subject>Sleep Stages</subject><subject>Toxicity: digestive system</subject><subject>Vomiting - prevention & control</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1983</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU2P0zAYhC0EWkrhxhXJB8SpKf5InPiCtFqxgLQSFzhbzps3ravULnayIv8eZ1tVcOBk2fNoxpoh5C1nW85k87E9wJbrRm5FWT8jK15JUfBG1M_JijFWF0wL9pK8SumQr5o19Q25UZJXrGQrArd-dAUecXRAse8dWJip9R0dw28Hbpxp6Km3rRuCxw21NM1-3D_hYP0i-OC6DXWeDpPfLY-AkcIejyFz0Z7m1-RFb4eEby7nmvy8__zj7mvx8P3Lt7vbhwIqJsaiYkrzRkpbtboF4KpBZhXvsVaqwroEsIoJXioOUosSOyH6trMt1wC6ZFquyaez72lqj9gB-jHawZyiO9o4m2Cd-Vfxbm924dEIxnmVu1yTDxeDGH5NmEZzdAlwGKzHMCXDZV2pWi1JmzMIMaQUsb-GcGaWUUwexSyjmDxKxt_9_bErfFkh6-8vuk1ghz7mDl26YrrSvGYyY8UZS1nxO4zmEKboc6X_i6Vn3ttxinj1y9DCLMgfKjywCQ</recordid><startdate>19831101</startdate><enddate>19831101</enddate><creator>Ahmedzai, S</creator><creator>Carlyle, D L</creator><creator>Calder, I T</creator><creator>Moran, F</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>5PM</scope></search><sort><creationdate>19831101</creationdate><title>Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy</title><author>Ahmedzai, S ; Carlyle, D L ; Calder, I T ; Moran, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c502t-50691833a5b9bcc168e0a61fe7665e74cca6021461c3924ed22fbdab19cc94093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1983</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antiemetics - adverse effects</topic><topic>Antiemetics - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Carcinoma, Small Cell - drug therapy</topic><topic>Clinical Trials as Topic</topic><topic>Dizziness - chemically induced</topic><topic>Double-Blind Method</topic><topic>Dronabinol - adverse effects</topic><topic>Dronabinol - analogs & derivatives</topic><topic>Dronabinol - therapeutic use</topic><topic>Drug Resistance</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Nausea - prevention & control</topic><topic>Oncology</topic><topic>original-article</topic><topic>Pharmacology. Drug treatments</topic><topic>Prochlorperazine - therapeutic use</topic><topic>Sleep Stages</topic><topic>Toxicity: digestive system</topic><topic>Vomiting - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ahmedzai, S</creatorcontrib><creatorcontrib>Carlyle, D L</creatorcontrib><creatorcontrib>Calder, I T</creatorcontrib><creatorcontrib>Moran, F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ahmedzai, S</au><au>Carlyle, D L</au><au>Calder, I T</au><au>Moran, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>1983-11-01</date><risdate>1983</risdate><volume>48</volume><issue>5</issue><spage>657</spage><epage>663</epage><pages>657-663</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Nabilone, a synthetic cannabinoid, and Prochlorperazine were compared in a double-blind crossover study of 34 patients with lung cancer undergoing a 3-day schedule of chemotherapy with Cyclophosphamide, Adriamycin and Etoposide. Symptom scores were significantly better for patients on nabilone for nausea, retching and vomiting (P less than 0.05). Fewer subjects vomited with nabilone (P = 0.05) and the number of vomiting episodes was lower (P less than 0.05); no patients on nabilone required additional parenteral anti-emetic. More patients preferred nabilone for anti-emetic control (P less than 0.005). Adverse effects common with nabilone were drowsiness (57%), postural dizziness (35%) and lightheadedness (18%). Euphoria was seen in 14% and a "high" in 7%. Erect systolic blood pressure was lower in nabilone patients on Day 1 (P = 0.05) but postural hypotension was a major problem in only 7%. Nabilone is an effective oral anti-emetic drug for moderately toxic chemotherapy, but the range and unpredictability of its side-effects warrant caution in its use.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>6315040</pmid><doi>10.1038/bjc.1983.247</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 1983-11, Vol.48 (5), p.657-663 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2011510 |
| source | MEDLINE; Nature Journals Online; EZB-FREE-00999 freely available EZB journals; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Antiemetics - adverse effects Antiemetics - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research Carcinoma, Small Cell - drug therapy Clinical Trials as Topic Dizziness - chemically induced Double-Blind Method Dronabinol - adverse effects Dronabinol - analogs & derivatives Dronabinol - therapeutic use Drug Resistance Drug toxicity and drugs side effects treatment Epidemiology Female Humans Lung Neoplasms - drug therapy Male Medical sciences Middle Aged Molecular Medicine Nausea - prevention & control Oncology original-article Pharmacology. Drug treatments Prochlorperazine - therapeutic use Sleep Stages Toxicity: digestive system Vomiting - prevention & control |
| title | Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T05%3A02%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-emetic%20efficacy%20and%20toxicity%20of%20nabilone,%20a%20synthetic%20cannabinoid,%20in%20lung%20cancer%20chemotherapy&rft.jtitle=British%20journal%20of%20cancer&rft.au=Ahmedzai,%20S&rft.date=1983-11-01&rft.volume=48&rft.issue=5&rft.spage=657&rft.epage=663&rft.pages=657-663&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.1983.247&rft_dat=%3Cproquest_pubme%3E13756769%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=13756769&rft_id=info:pmid/6315040&rfr_iscdi=true |